Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)
Stefan Halbherr, Stefanie Lerch, Sebastian Bellwald, Petra Polakova, Bettina Bannert, Marie Roumet, Roch-Philippe Charles, Martin A. Walter, Corrado Bernasconi, Camille Peitsch, Pascal C. Baumgartner, Céline Kaufmann, Heinrich P. Mattle, Alain Kaelin-Lang, Andreas Hartmann, Michael Schuepbach
{"title":"Safety and tolerability of intravenous liposomal GM1 in patients with Parkinson disease: A single center open-label clinical phase I trial (NEON trial)","authors":"Stefan Halbherr, Stefanie Lerch, Sebastian Bellwald, Petra Polakova, Bettina Bannert, Marie Roumet, Roch-Philippe Charles, Martin A. Walter, Corrado Bernasconi, Camille Peitsch, Pascal C. Baumgartner, Céline Kaufmann, Heinrich P. Mattle, Alain Kaelin-Lang, Andreas Hartmann, Michael Schuepbach","doi":"10.1101/2024.09.05.24313105","DOIUrl":null,"url":null,"abstract":"<strong>Background:</strong> Parkinson disease (PD) is a chronic progressive neurodegenerative disorder leading to motor and non- motor impairment often resulting in severe loss of quality of life. There are symptomatic treatments without effect on the progression of PD. A disease-modifying treatment that could ideally stop the neurodegenerative process is direly needed. Monosialotetrahexosylganglioside (GM1) is a promising molecule with neuroprotective effects in preclinical models of PD and has yielded encouraging results in patients with PD in a randomized placebo-controlled trial. Talineuren (TLN) is a liposomal formulation of GM1 that has been shown to cross the blood-brain barrier in animals. We assessed the safety and pharmacokinetics of TLN in patients with PD.","PeriodicalId":501367,"journal":{"name":"medRxiv - Neurology","volume":"26 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"medRxiv - Neurology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1101/2024.09.05.24313105","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Parkinson disease (PD) is a chronic progressive neurodegenerative disorder leading to motor and non- motor impairment often resulting in severe loss of quality of life. There are symptomatic treatments without effect on the progression of PD. A disease-modifying treatment that could ideally stop the neurodegenerative process is direly needed. Monosialotetrahexosylganglioside (GM1) is a promising molecule with neuroprotective effects in preclinical models of PD and has yielded encouraging results in patients with PD in a randomized placebo-controlled trial. Talineuren (TLN) is a liposomal formulation of GM1 that has been shown to cross the blood-brain barrier in animals. We assessed the safety and pharmacokinetics of TLN in patients with PD.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
